Go to Wolters Kluwer VitalLaw.comGo to Wolters Kluwer VitalLaw.com
VitalLaw®
  • Find answers to your questions
  • Log in to access your subscriptions
In depth. On point.
In depth. On point.
  • Home
  • Legal Directory
  • Home
  • Legal Directory
In depth. On point.
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations
    • CONTROLLED SUBSTANCES—SETTLEMENT AGREEMENTS: CVS to pay $315M to settle FCA, CSA allegations
    • ADMINISTRATION OF MEDICARE/MEDICAID PROGRAMS—DAB DECISIONS: Affiliation with revoked hospice supported Medicare enrollment revocation, preclusion list placement
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • ADMINISTRATION OF MEDICARE/MEDICAID PROGRAMS—DAB DECISIONS: License revocation related to professional performance supports federal health care program exclusion
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • ELECTRONIC HEALTH RECORDS—E.D. Mo.: Case against pharmaceutical company after data breach moves forwardE.D. Mo.: Case against pharmaceutical company after data breach moves forward
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • EXPERT INSIGHTS—Seals and sale bans: California's new non-UPF certification and age limits on dietary supplements & OTC diet products
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • FALSE CLAIMS ACT—SETTLEMENT AGREEMENTS: Heal 360 clinics, owner reach $20 million settlement to resolve FCA allegations
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • FOOD STANDARDS—FINAL RULES: FDA amends standard of identity regulations regarding salt substitutes
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • HEALTH CARE COMPLIANCE NEWS—OIG Work Plan updates for September 2026
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • LABELING AND PACKAGING (FOOD, DRUGS & MEDICAL DEVICES)—S.D. Cal.: Natural-labeling claims advance over manufactured citric acid
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • LAW FIRM NEWS—Noteworthy developments in the legal community
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • MEDICAID—Tex. Sup. Ct.: Orthodontia prior-authorization contractor not an ‘individual’ for purposes of interlocutory appeals jurisdiction
      • You have 1 more complimentary views available this month. Log in if you are already a customer
    • SAFETY AND EFFECTIVENESS—NOTICES: FDA’s LASIX determination allows for continued approval of ANDAs
      • You have 1 more complimentary views available this month. Log in if you are already a customer
  • Articles
    • Articles
  • Law Firms
    • Law Firms
  • Organizations
    • Organizations

    Health Law Daily Wrap Up, SAFETY AND EFFECTIVENESS—NOTICES: FDA’s LASIX determination allows for continued approval of ANDAs, (Oct 16, 2026)

    By WK Editorial Staff

    The FDA has determined that LASIX (furosemide) oral solution, 10 milligrams (mg)/ milliliter (mL), was not withdrawn from sale for reasons of safety or effectiveness.

    This determination means that the FDA will not begin procedures to withdraw approval ...

    © 2026 CCH Incorporated and its affiliates and licensors. All rights reserved.

    • Manage Cookie Preferences
    • Privacy Statement
    • Terms of Use